More to Life than NF-κB in TNFR1 Signaling

Trends in Immunology

Volumn 37, Issue 8, 2016, Pages 535-545

  Ting, Adrian T ^a   Bertrand, Mathieu J M ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; POLYUBIQUITIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); TUMOR NECROSIS FACTOR RECEPTOR 1; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; PROTEIN BINDING;

CELL DEATH; CELL FUNCTION; ENZYME INACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PROTEIN PHOSPHORYLATION; REVIEW; SURVIVAL; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASM; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; CELL DEATH; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEOPLASMS; NF-KAPPA B; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION;

EID: 84979523727     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.06.002     Document Type: Review

References (78)

1. 1 Kolb, W.P., Granger, G.A., Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc. Natl. Acad. Sci. U.S.A. 61 (1968), 1250–1255.
2. 2 Ruddle, N.H., Waksman, B.H., Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. 3. Analysis of mechanism. J. Exp. Med. 128 (1968), 1267–1279.
3. 3 Kalliolias, G.D., Ivashkiv, L.B., TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12 (2016), 49–62.
4. 4 Pasparakis, M., Vandenabeele, P., Necroptosis and its role in inflammation. Nature 517 (2015), 311–320.
5. 5 Hsu, H., et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84 (1996), 299–308.
6. 6 Micheau, O., Tschopp, J., Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003), 181–190.
7. 7 Van Antwerp, D.J., et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274 (1996), 787–789.
8. 8 O'Donnell, M.A., et al. Ubiquitination of RIP1 regulates an NF-κB-independent cell-death switch in TNF signaling. Curr. Biol. 17 (2007), 418–424.
9. 9 O'Donnell, M.A., et al. NEMO inhibits programmed necrosis in an NFκB-independent manner by restraining RIP1. PLoS ONE, 7, 2012, e41238.
10. 10 Legarda-Addison, D., et al. NEMO/IKKgamma regulates an early NF-κB-independent cell-death checkpoint during TNF signaling. Cell Death Differ. 16 (2009), 1279–1288.
11. 11 Dondelinger, Y., et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 20 (2013), 1381–1392.
12. 12 Vlantis, K., et al. NEMO prevents RIP Kinase 1-mediated epithelial cell death and chronic intestinal inflammation by NF-κB-dependent and -independent functions. Immunity 44 (2016), 553–567.
13. 13 Dondelinger, Y., et al. NF-κB-independent role of IκKα/IκKβ in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol. Cell 60 (2015), 63–76.
14. 14 Vince, J.E., et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (TNF) to efficiently activate NF-κB and to prevent TNF-induced apoptosis. J. Biol. Chem. 284 (2009), 35906–35915.
15. 15 Haas, T.L., et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36 (2009), 831–844.
16. 16 Dynek, J.N., et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29 (2010), 4198–4209.
17. 17 Gerlach, B., et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471 (2011), 591–596.
18. 18 Varfolomeev, E., et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation. J. Biol. Chem. 283 (2008), 24295–24299.
19. 19 Mahoney, D.J., et al. Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 11778–11783.
20. 20 Bertrand, M.J., et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30 (2009), 789–801.
21. 21 Park, S.M., et al. Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett. 566 (2004), 151–156.
22. 22 Tokunaga, F., et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat. Cell Biol. 11 (2009), 123–132.
23. 23 Draber, P., et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep. 13 (2015), 2258–2272.
24. 24 Kanayama, A., et al. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol. Cell 15 (2004), 535–548.
25. 25 Ea, C.K., et al. Activation of IκK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22 (2006), 245–257.
26. 26 Wu, C.J., et al. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation [corrected]. Nat. Cell Biol. 8 (2006), 398–406.
27. 27 Komander, D., et al. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10 (2009), 466–473.
28. 28 Rahighi, S., et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 136 (2009), 1098–1109.
29. 29 Emmerich, C.H., et al. Activation of the canonical IκK complex by K63/M1-linked hybrid ubiquitin chains. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 15247–15252.
30. 30 Hayden, M.S., Ghosh, S., Regulation of NF-κB by TNF family cytokines. Semin. Immunol. 26 (2014), 253–266.
31. 31 Wertz, I.E., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430 (2004), 694–699.
32. 32 Mevissen, T.E., et al. OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell 154 (2013), 169–184.
33. 33 De, A., et al. The deubiquitinase activity of A20 is dispensable for NF-κB signaling. EMBO Rep. 15 (2014), 775–783.
34. 34 Lu, T.T., et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 38 (2013), 896–905.
35. 35 Wright, A., et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev. Cell 13 (2007), 705–716.
36. 36 Kovalenko, A., et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424 (2003), 801–805.
37. 37 Trompouki, E., et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424 (2003), 793–796.
38. 38 Brummelkamp, T.R., et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424 (2003), 797–801.
39. 39 Salvesen, G.S., Walsh, C.M., Functions of caspase 8: the identified and the mysterious. Semin. Immunol. 26 (2014), 246–252.
40. 40 Tsuchiya, Y., et al. FLIP the switch: regulation of apoptosis and necroptosis by cFLIP. Int. J. Mol. Sci. 16 (2015), 30321–30341.
41. 41 Dannappel, M., et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513 (2014), 90–94.
42. 42 Takahashi, N., et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513 (2014), 95–99.
43. 43 Kelliher, M.A., et al. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8 (1998), 297–303.
44. 44 Blackwell, K., et al. Two coordinated mechanisms underlie tumor necrosis factor α-induced immediate and delayed IκB kinase activation. Mol. Cell. Biol. 33 (2013), 1901–1915.
45. 45 Gentle, I.E., et al. In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-κB and activation of caspase-8. J. Biol. Chem. 286 (2011), 13282–13291.
46. 46 Wong, W.W., et al. RIPK1 is not essential for TNFR1-induced activation of NF-κB. Cell Death Differ. 17 (2010), 482–487.
47. 47 Wang, L., et al. TNF-α induces two distinct caspase-8 activation pathways. Cell 133 (2008), 693–703.
48. 48 Wilson, N.S., et al. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 10 (2009), 348–355.
49. 49 Karin, M., Lin, A., NF-κB at the crossroads of life and death. Nat. Immunol. 3 (2002), 221–227.
50. 50 Bertrand, M.J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 Ligases that promote RIP1 ubiquitination. Mol. Cell 30 (2008), 689–700.
51. 51 Petersen, S.L., et al. Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12 (2007), 445–456.
52. 52 Moulin, M., et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J. 31 (2012), 1679–1691.
53. 53 Berger, S.B., et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J. Immunol. 192 (2014), 5476–5480.
54. 54 Peltzer, N., et al. HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Rep. 9 (2014), 153–165.
55. 55 Rickard, J.A., et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife, 3, 2014, e03464.
56. 56 Kondylis, V., et al. NEMO prevents steatohepatitis and hepatocellular carcinoma by inhibiting RIPK1 kinase activity-mediated hepatocyte apoptosis. Cancer Cell 28 (2015), 582–598.
57. 57 Linkermann, A., Green, D.R., Necroptosis. N. Engl. J. Med. 370 (2014), 455–465.
58. 58 O'Donnell, M.A., et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13 (2011), 1437–1442.
59. 59 Wertz, I.E., et al. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 528 (2015), 370–375.
60. 60 Thein, S., et al. IκK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem. Biophys. Res. Commun. 450 (2014), 550–554.
61. 61 Li, X., et al. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416 (2002), 345–347.
62. 62 Fotin-Mleczek, M., et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J. Cell Sci. 115 (2002), 2757–2770.
63. 63 Boutaffala, L., et al. NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis. Cell Death Differ. 22 (2015), 2020–2033.
64. 64 McQuade, T., et al. Positive and negative phosphorylation regulates RIP1- and RIP3-induced programmed necrosis. Biochem. J. 456 (2013), 409–415.
65. 65 Vanlangenakker, N., et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 18 (2011), 656–665.
66. 66 He, S., et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 137 (2009), 1100–1111.
67. 67 Vince, J.E., et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFα. J. Cell Biol. 182 (2008), 171–184.
68. 68 Varfolomeev, E., et al. Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors. Sci. Signal., 5, 2012, ra22.
69. 69 Old, L.J., Tumor necrosis factor (TNF). Science 230 (1985), 630–632.
70. 70 Yatim, N., et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 350 (2015), 328–334.
71. 71 Mocarski, E.S., et al. Necroptosis: the Trojan horse in cell autonomous antiviral host defense. Virology 479–480 (2015), 160–166.
72. 72 Kumari, S., et al. Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis. Elife, 3, 2014, e03422.
73. 73 Pai, S.Y., et al. Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-κB essential modulator deficiency. J. Allergy Clin. Immunol., 122, 2008 1113–1118 e1.
74. 74 Hanson, E.P., et al. Hypomorphic nuclear factor-κB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J. Allergy Clin. Immunol., 122, 2008 1169–1177 e16.
75. 75 Mizukami, T., et al. Successful treatment with infliximab for inflammatory colitis in a patient with X-linked anhidrotic ectodermal dysplasia with immunodeficiency. J. Clin. Immunol. 32 (2012), 39–49.
76. 76 Boisson, B., et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat. Immunol. 13 (2012), 1178–1186.
77. 77 Boisson, B., et al. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J. Exp. Med. 212 (2015), 939–951.
78. 78 Fulda, S., Vucic, D., Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug. Discov. 11 (2012), 109–124.